MorphoSys Clinical Trial Data And Deals
Edison | Feb 09, 2013 10:25PM ET
The presentation of data and completion of deals by MorphoSys (MOR.DE) marked Q412 as an important time for the company. Data presented on MOR103, MOR208 and a product related to MOR202 indicated the potential of its proprietary pipeline. The amendments to its long-term collaboration with Novartis are expected to lead to new discovery alliances and extra resources for its proprietary pipeline. The sale of its AbD Serotec division for a net consideration of €48m has also generated additional funds for MorphoSys to invest in its own products. The next significant event that could occur is the partnering of MOR103. We have raised our valuation to €804m.
More data on MOR103 and MOR208
Additional data from the Phase Ib/IIa study in RA with MOR103 were presented at the American College of Rheumatology (ACR) meeting in November, which re-affirmed the product’s potential in RA. The likelihood of MorphoSys finding a partner was further increased by Phase I data showing that a subcutaneous formulation of MOR103 has favourable pharmaco-kinetics/pharmacodynamics. Also, promising data from a Phase I trial with MOR208 in chronic lymphcytic leukaemia was presented at the ASH conference in December.
Novartis alliance now includes Ylanthia
The long-term collaboration with Novartis has been amended so that MorphoSys will use its new antibody platform, Ylanthia, to develop antibodies for Novartis (NVS). This shows that Novartis has been convinced of the benefits of the Ylanthia platform over HuCAL. It also enables MorphoSys to form antibody discovery alliances with other companies, as the exclusivity condition in the original contract no longer exists.
Disposal of AbD Serotec
MorphoSys has sold its AbD Serotec in a favourable deal to Bio-Rad for a net amount of c €48m. The company is now able to focus its efforts on developing therapeutic products and has greater resources available to invest in its proprietary pipeline.
Valuation: DCF valuation of €804m
We have raised our valuation by €107m to €804m (€34.77 per share) after a detailed review. Substantial changes have also been made to estimates, primarily because of the sale of AbD Serotec and expected increases in proprietary R&D spending, and we have restated FY11 numbers for the deal. The main event that could lead to a re-rating of the shares is the potential partnering of MOR103, which we estimate would increase our valuation to c €850m (€37.00 per share).
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.